Otide - Exporter & Manufacturer, New Delhi, India

UNITED BIOTECH (P) LTD.

Otide

Product Code : 04

[Select]

Product Specification

Otide:
Stems The Tide, Revives The Life.
Synthetic Analogue of Somatostatin.
Superior than Somatostatin:

Subcutaneous administration
Longer half life (2hr.) than Somatostatin (1-2min.)
No rebound hypersecretion of hormones takes place.
20 fold greater potency than somatostatin in suppressing GH secretion.

Acromegaly:

OTIDE normalizes GH values in most acromegalic patients (73.8%)
Effective in reducing the headache, joint pain, excessive perspiration cardiomyopathy and sleep apnea associated with acromegaly.
Octreotide is an effective treatment for acromegaly that may be used as primaryy therapy or after surgery and or pituitary irradiation.

Stems The Tide, Revives The Life:

Long acting octapeptide (half-life 100min.)
Rapid onset of action
Not only inhibits the release of pituitary growth hormone but also inhibits the secretion of endocrine of the pancreas, stomach and intestine.
Highly resistant to enzymatic degradation.
Inhibits gall bladder contractility and bile flow.
More effective than vasopressin in initial controlling of acute esophageal variceal bleeding.
Reduces the risk of complications after elective pancreatic surgery.

Variceal Bleeding:

Combination of sclerotherapy and OTIDE is more effective than sclerotherapy alone in controlling acute variceal bleeding.
OTIDE infusion is effective for control of variceal bleeding.
Reduces the rate of recurrent variceal haemorrhage in patients with cirrhotic portal hypertension.

Anticancer action:

Direct antiproliferative effects on tumor cells, mediated by somatostatin receptors.
Achieves biochemical control of GH (Growth Hormone) and IGF-I in 50-60% of patients and tumour shrinkage in some 30% of patients.
OTIDE administration significantly improves survival and is a valuable alternative in the treatment of inoperable Hepatocellular carcinoma.

Stems The Tide, Revives The Life:
Radiation Induced Diarrhoea
Mucosal crypt cell aberrations - Epithelial flattening
Increases GI Fluid Secretion - Cell degradation

OTIDE Reduces splanchnic blood flow
Inhibits neuroendocrine secretion
Inhibits small intestinal motility
Enhances absorption of water and electrolyte.

Dosage: 150 mcg/day S.C. (50 mcg T.I.D.)

In Cirrhosis & Portal Hypertension:

Decreases splanchnic blood flow of patients with portal hypertension
Inhibits postprandial release of glucagons
Reduces portal pressure and azygous blood flow
Inhibits the gastric secretion of acid as well pepsin
Most effective therapy.

Randomized clinical trials have shown OTIDE to be more effective than placebo, vasopressin and ballon tamponade in controlling acute variceal hemorrhage with minimal side effects.

Safer agent for long term therapy in patients with portal hypertension.

Long-term OTIDE treatment persistently suppresses the postprandial glucagons response of patients with portal hypertension without causing deterioration in their renal function.

Indications:

Emergency management of bleeding esophageal varices.
Acromegaly
Post high risk Pancreatic surgery
Gastro-entero-pancreatic (GEP) endocrine tumors.
Diarrhoea associated with radiotherapy and chemotherapy

Dosage & Administration:

Acromegaly	0.05 - 0.1 mg by s.c. inj. every 8 or 12 hours
Emergency management of bleeding esophageal varices	25 mcg / hr for 5 days by continuous i.v. Infusion
Post high risk pancreatic Surgery	0.1 mg t.i.d. by s.c.
Radiation induced diarrhoea	150 mcg/day S.C. (50 mcg. T.I.D.)
Gastro-entero-pancreatic Endocrine tumors	0.05 mg o.d. / twice daily by s.c. inj.
In elderly & patients with impaired renal function	No dose adjustment required

Other Products in 'Drugs & Medications' category

Follitec	Tecoplan	Docetaxel Injection Concentrate	Netmicin	Terlipressin Injection	Menem

View all products(15)

<< Back

The membership of this company with Tradeindia has expired. To view other companies related to this industry, kindly Click Here